Go Pro
NASDAQ:MSLE

Satellos Bioscience Q4 2025 Earnings Report

$10.01 -0.02 (-0.20%)
As of 08/10/2026 04:00 PM Eastern

Satellos Bioscience EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.36
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A

Satellos Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Satellos Bioscience Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Friday, March 27, 2026
Conference Call Time
8:00AM ET

Satellos Bioscience Earnings Headlines

Satellos Bioscience Inc
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Satellos Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Satellos Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Satellos Bioscience and other key companies, straight to your email.

About Satellos Bioscience

Satellos Bioscience (NASDAQ:MSLE) is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.

View Satellos Bioscience Profile